Radionuclide development at BNL for nuclear medicine therapy
Radionuclide development at BNL for nuclear medicine therapy
复制标题
DOI：
10.1016/s0969-8043(97)00040-7
复制
发表时间：
1998-04-01
影响因子：
1.6
通讯作者：
Srivastava, SC
中科院分区：
文献类型：
--
作者：
Mausner, LF;Kolsky, KL;Srivastava, SC
具有中等能量β发射和几天半衰期的放射性核素通常被视为放射免疫疗法的有吸引力的候选者。在这一类中最有希望的是Sc-47、Cu-67、Sm-153、Re-188和Au-199。本文综述了北京原子能研究所Cu-67、Sm-153、Au-199的生产情况，并详细介绍了该应用的最新候选材料Sc-47的开发情况。我们还总结了另一种重要的治疗性放射性核素Sn-117 m用于骨痛缓解的发展。(C)1998爱思唯尔科技有限公司版权所有。
Radionuclides with medium energy beta emission and a several day half-life have often been viewed as attractive candidates for radioimmunotherapy. Among the most promising in this category are Sc-47, Cu-67, Sm-153, Re-188, and Au-199. The production of Cu-67, Sm-153, Au-199 at BNL is summarized and the development of the latest candidate for this application, Sc-47, is described in detail. We also summarize the development of another important therapeutic radionuclide, Sn-117m for bone pain palliation. (C) 1998 Elsevier Science Ltd. All rights reserved.